BioSpace News Archive

Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or “the Company”), a biotechnology company developing novel LAG-3-related immunotherapy treatments for cancer and autoimmune disease, provides a clinical development update for its first-in-class LAG-3 antigen-presenting cell (APC) activator product candidate, eftilagimod alpha (“efti”).

Adverum Biotechnologies, Inc. (Nasdaq: ADVM) today announced that the first subject was dosed in the LUNA Phase 2 trial evaluating ixoberogene soroparvovec (Ixo-vec, formerly referred to as ADVM-022) for the treatment of wet age-related macular degeneration (wet AMD).

AIVITA Biomedical, Inc., a biotech company specializing in innovative cell applications, announced that chairman and CEO Hans Keirstead, Ph.D., has received the Orange County Business Journal’s 2022 Innovator of the Year Award.

Smith+Nephew (LSE:SN, NYSE: SNN), the global medical technology company, today announces promising new data furthering a number of published studies supporting the use of its REGENETEN Bioinductive Implant in rotator cuff repair.

The US Patent Office has issued Patent 11,439,590 to Scott Karolchyk (NDS) and Jeffrey Liegner MD (ECNW) for the legacy formulation of ophthalmic formulations containing corticosteroids combined with various antibiotics, using safe and superior-performing excipients that are comfortable in the eye.

Tenon Medical, Inc. today announced that management will present during Benzinga’s All Access investor event taking place Friday, September 16, 2022.

Fabric Genomics, Inc., a leader in AI-driven precision medicine, announced that it has appointed Sean Hofherr, PhD, FACMG, as Chief Operating Officer and Clinical Director.

Medicomp Systems, a physician-driven provider of diagnostically connected patient data solutions, announced today that the United States Patent and Trademark Office (USPTO) has awarded Medicomp US Patent 10,600,505 for the intelligent prompting of protocols.

Stryker (NYSE:SYK) today announced the launch of its Pulse Intelligent Delivery Platform, a full-circle product and fulfillment offering optimized for high volume foot and ankle procedures in the ambulatory surgery center (ASC) setting, which will debut at the 2022 American Orthopaedic Foot & Ankle Society Annual Meeting (AOFAS).

IPA (ImmunoPrecise ANTIBODIES LTD.) (the “Company” or “IPA”) (NASDAQ: IPA) (TSXV: IPA), an advanced biotherapeutic research and technology company, today announced financial results for first quarter fiscal year 2023, which ended July 31, 2022.